Jim Simons Actinium Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$7.15 - $9.39 $385,370 - $506,102	-53,898 Reduced 52.74%	48,302 $358,000
Q1 2023 May 12, 2023	SELL	$8.51 - $14.26 $488,474 - $818,524	-57,400 Reduced 35.96%	102,200 $966,000
Q4 2022 Feb 13, 2023	BUY	$9.71 - $12.51 $789,423 - $1.02 Million	81,300 Added 103.83%	159,600 $1.7 Million
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $99,085 - $174,688	20,600 Added 35.7%	78,300 $578,000
Q2 2022 Aug 12, 2022	BUY	$4.71 - $7.11 $271,767 - $410,247	57,700 New	57,700 $278,000

6.65M

369K

148K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.